Endocyte, Inc. (NASDAQ:ECYT) was upgraded by investment analysts at Wedbush from a “neutral” rating to an “outperform” rating in a research note issued on Tuesday. The firm presently has a $7.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $2.00. Wedbush’s target price points to a potential upside of 14.75% from the stock’s previous close.

A number of other brokerages have also issued reports on ECYT. ValuEngine raised Endocyte from a “strong sell” rating to a “sell” rating in a research report on Monday. Zacks Investment Research lowered Endocyte from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $7.00.

Endocyte (NASDAQ ECYT) traded down 5.90% on Tuesday, hitting $5.74. The stock had a trading volume of 2,705,365 shares. Endocyte has a 12-month low of $1.17 and a 12-month high of $6.55. The firm’s market cap is $244.38 million. The company’s 50 day moving average is $1.69 and its 200 day moving average is $1.88.

Endocyte (NASDAQ:ECYT) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.03). Endocyte had a negative return on equity of 32.68% and a negative net margin of 61,437.14%. The business had revenue of $0.01 million for the quarter. During the same quarter last year, the firm posted ($0.25) earnings per share. On average, equities research analysts expect that Endocyte will post ($1.06) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/05/wedbush-upgrades-endocyte-inc-ecyt-to-outperform.html.

Institutional investors have recently made changes to their positions in the stock. Stifel Financial Corp increased its holdings in Endocyte by 3.9% in the first quarter. Stifel Financial Corp now owns 45,353 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 1,711 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Endocyte by 34.1% in the second quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 25,003 shares during the last quarter. Teachers Advisors LLC increased its holdings in Endocyte by 17.1% in the fourth quarter. Teachers Advisors LLC now owns 65,119 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 9,506 shares during the last quarter. Spark Investment Management LLC bought a new stake in Endocyte in the second quarter valued at about $177,000. Finally, LMR Partners LLP bought a new stake in Endocyte in the second quarter valued at about $196,000. 28.80% of the stock is owned by hedge funds and other institutional investors.

About Endocyte

Receive News & Stock Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related stocks with our FREE daily email newsletter.